Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
about
Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemiaAllogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.Hematopoietic stem cell transplantation for MDS.Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: BloodComparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignanciesThe role of the marrow microenvironment in hematopoietic stem cell transplantation.Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia?Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic maAllogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.Who is fit for allogeneic transplantation?Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and MarrowThe Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxisGraft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioningImmunotherapy following hematopoietic stem cell transplantation: potential for synergistic effectsAllogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patientsEarly hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS.Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and MSignificant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS).Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms.Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic SyndromeChanging the treatment paradigm in myelodysplastic syndromes.Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation.TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.The evolution of hematopoietic SCT in myelodysplastic syndrome.Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
P2860
Q28307278-986EF125-AAC4-4FFC-BBE0-E427BE1C7C05Q30274942-58CCB50D-CB73-4B67-A006-F1B4FDFBD971Q30675919-654755BC-4D15-4D67-9589-7F49232646EBQ33393647-AC468C17-35F7-490E-9303-991313E649CFQ33560410-4A649587-3D86-47D0-907C-9C7DDB880309Q33767314-59C7AB31-3C0B-425B-A95B-362E3CE1EC82Q33771667-9CAE476F-B46E-4A50-9235-6C33296675ABQ34217884-372D7AA3-0335-4DE0-A0C5-4B2A183291B8Q34360641-B64D4680-95F2-4C0A-A045-1EB9AA663515Q34463645-15946B52-4AA9-4505-837D-4A5071CD674BQ34485594-CFA4A10B-1C04-4AF3-816E-2764BFE12373Q35000581-3F2780A0-CEB5-468A-84D4-1A88C5C90210Q35202588-4F5BACBB-B7E0-4D12-AA2F-16E48FBD2973Q35317371-FE962BB8-EDFD-49C2-A740-CAB5768B07ABQ35605318-C1FF0397-8984-4FB6-83FF-FB65E505C136Q35608022-AFE0E874-1081-4F17-B82D-BAC6C43456F9Q35660739-5E3C283F-072A-4AC1-A9A2-494F0F0FE019Q35714782-F2E63B31-82E6-47CB-892C-28A888152000Q35849342-BDE5D4FA-86A0-43EF-8FD7-991F2C8744D3Q35854094-5A6B7F2C-7A38-4FC7-8D3A-1163C00BE4EAQ35953348-C91949A2-8A2F-43A2-B5F8-15DD2AAB2629Q36206849-CA364B7A-A8F4-47CD-A4B0-412CB95EBD1BQ36319726-CE486352-A771-461B-9BB6-60BE474688FFQ36380188-42C92394-A4EC-4DCE-9C05-597E13E9E473Q36431041-186D9BC6-8F3B-43C8-80CE-3FA02C781212Q36742108-6280E93C-E99B-430F-AAD9-9CE8E8D399B9Q36890784-CED45F0F-E563-43AB-A64C-94630404F485Q36920394-41CCA9B0-4EF2-45D6-AC00-3EDED2DC4271Q36951734-04891C4D-8D48-4C91-A49A-F43BE6640022Q36967029-386F5D99-CA0E-4842-94A5-D469058B5E07Q37169115-DBFC7420-8F4C-43D7-A839-AA76E94B7FFEQ37205584-6B5C5F0B-7504-4177-BE59-5C6A69E59ADEQ37207443-021683B6-9456-4B68-A029-3B81D6E869A9Q37277994-B4E22DB9-8B5C-479F-9D47-6DB3A0200824Q37284406-97A9239C-0EEF-43DE-8FA7-870F8DD12062Q37291642-174F6706-FC60-4073-BEC6-2256E69BF342Q37375545-047F5CCA-FC26-406C-AFD8-17C2BE508B09Q37404489-4D9A71CF-A637-492F-8E2A-20A44E01CB2AQ37706850-B63F27A5-EA83-47D8-BDDB-D34BE7B7ECC4Q37718826-5DE0C4BD-959A-4847-B97B-188E279CAD4D
P2860
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Reduced-intensity conditioning ...... myeloproliferative disorders.
@ast
Reduced-intensity conditioning ...... myeloproliferative disorders.
@en
type
label
Reduced-intensity conditioning ...... myeloproliferative disorders.
@ast
Reduced-intensity conditioning ...... myeloproliferative disorders.
@en
prefLabel
Reduced-intensity conditioning ...... myeloproliferative disorders.
@ast
Reduced-intensity conditioning ...... myeloproliferative disorders.
@en
P2093
P2860
P50
P1476
Reduced-intensity conditioning ...... myeloproliferative disorders.
@en
P2093
Bart L Scott
Benedetto Bruno
Edward D Agura
Elliot Epner
Finn B Petersen
Ginna G Laport
James C Wade
Karl G Blume
Michael B Maris
Monic J Stuart
P2860
P304
P356
10.1016/J.BBMT.2007.11.012
P577
2008-02-01T00:00:00Z